CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:HBO1 determines epithelial-mesenchymal transition and promotes immunotherapy resistance in ovarian cancer cells.
HBO1 determines epithelial-mesenchymal transition and promotes immunotherapy resistance in ovarian cancer cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
HBO1 作为一种关键的癌因子,驱动 EMT 并促进卵巢癌细胞的免疫治疗耐药。
上皮-间质转化(EMT)在卵巢癌(OC)的肿瘤进展和治疗耐药中发挥重要作用,而卵巢癌是女性致死率最高的妇科恶性肿瘤之一;但其细胞内在的EMT机制尚未充分阐明。
以TGF-β处理SKOV3卵巢癌细胞诱导EMT,或使用TGF-β通路抑制剂SB431542降低细胞迁移。通过敲低或过表达SKOV3细胞中的HBO1,验证其在EMT中的作用;以流式细胞术分析HBO1对细胞增殖和凋亡的影响;利用全基因组转录组比较对照与HBO1敲低细胞的差异基因;采用IVIS光谱系统进行T细胞细胞毒实验,并以CUT&Tag测序检测HBO1染色质结合情况。
HBO1是一种MYST组蛋白乙酰转移酶(HAT),是卵巢癌细胞内在EMT的决定因素。TGF-β诱导SKOV3细胞EMT期间以及临床卵巢癌晚期样本中,HBO1均显著升高。敲低HBO1可阻断TGF-β诱导的EMT、细胞迁移和侵袭,并抑制体内肿瘤形成。有趣的是,敲低HBO1还可降低SKOV3细胞对CAR-T 细胞的耐受。机制上,HBO1与SMAD4共同结合EMT相关基因集,并协调驱动SKOV3细胞肿瘤进展的基因调控网络。
HBO1是驱动卵巢癌细胞EMT并促进免疫治疗耐药的关键致癌因子。本研究揭示了HBO1介导的表观遗传机制在卵巢癌进展中的重要作用,为设计新治疗策略提供了依据。
Epithelial-mesenchymal transition (EMT) plays critical roles in tumor progress and treatment resistance of ovarian cancer (OC), resulting in the most deadly gynecological cancer in women. However, the cell-intrinsic mechanism underlying EMT in OC remains less illuminated. METHOD: SKOV3, the OC cell line, was treated with TGF- to induce EMT or with SB431542, an inhibitor of the TGF- signaling pathway, to reduce migration. The function of HBO1 in EMT was confirmed by knock-down or overexpression of HBO1 in SKOV3 cells. The role of HBO1 in cell proliferation and apoptosis of SKOV3 cells was analyzed by flow cytometry. The whole-genome transcriptome was used to compare significantly different genes in control and HBO1-KD SKOV3 cells. T-cell cytotoxicity assays were measured by an IVIS spectrum. The chromatin binding of HBO1 was investigated using CUT&Tag-seq.
Here, we show that HBO1, a MYST histone acetyltransferase (HAT), is a cell-intrinsic determinant for EMT in OC cells. HBO1 is greatly elevated during TGF- -triggered EMT in SKOV3 OC cells as well as in later stages of clinical OC samples. HBO1 Knock-down (KD) in SKOV3 cells blocks TGF- -triggered EMT, migration, invasion and tumor formation in vivo. Interestingly, HBO1 KD in SKOV3 cells suppresses their resistance to CAR-T cells. Mechanistically, HBO1 co-binds the gene sets responsible for EMT with SMAD4 and orchestrates a gene regulatory network critical for tumor progression in SKOV3 cells.
HBO1 plays an essential onco-factor to drive EMT and promote the immunotherapy resistance in ovarian cancer cells. Together, we reveal a critical role of HBO1 mediated epigenetic mechanism in OC progression, providing an insight into designing new therapy strategies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。